Dolutegravir + Abacavir + Lamivudine bulk supplier for pharma manufacturers

Dolutegravir + Abacavir + Lamivudine 50 mg / 600 mg / 300 mg Suppliers & Bulk Manufacturers

Available Forms: Tablet

Available Strengths: 50 mg / 600 mg / 300 mg

Reference Brands: Triumeq(US & EU)

Dolutegravir + Abacavir + Lamivudine, sold as Triumeq, is a once-daily HIV-1 treatment combining three antiretrovirals in one pill. It offers strong viral suppression, is FDA and EMA approved, and is recommended for patients who are HLA-B*5701 negative.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

Product Description:

Dolutegravir + Abacavir + Lamivudine is a fixed-dose combination antiretroviral medication used for the treatment of HIV-1 infection. Marketed under the brand name Triumeq, this once-daily oral tablet combines Dolutegravir (an integrase inhibitor), Abacavir, and Lamivudine (both NRTIs) to block HIV replication and reduce viral load. Approved by the US FDA and EMA, it is recommended for adults and adolescents who are HLA-B*5701 negative, with no resistance to any of the components. Triumeq simplifies HIV treatment by combining three powerful agents in one pill, offering high efficacy, strong viral suppression, and improved adherence for long-term HIV management.

Dolutegravir + Abacavir + Lamivudine — third party manufacturing & bulk supply

Dolutegravir + Abacavir + Lamivudine 50 mg / 600 mg / 300 mg is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Dolutegravir + Abacavir + Lamivudine is supplied as Tablet — an oral solid dosage form, so the indicative MOQ is 200,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Dolutegravir + Abacavir + Lamivudine listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Dolutegravir + Abacavir + Lamivudine →

Back to Listing

Frequently Asked Questions

Dolutegravir, abacavir, and lamivudine are used together as a complete once-daily regimen for the treatment of HIV-1 infection in adults and adolescents. This fixed-dose combination helps suppress viral replication, improve immune function, and reduce the overall pill burden for patients requiring long-term antiretroviral therapy.

It is made from Dolutegravir, an integrase strand transfer inhibitor; Abacavir, a nucleoside reverse transcriptase inhibitor; and Lamivudine, another nucleoside reverse transcriptase inhibitor. These three components act through different mechanisms to stop HIV replication effectively.

The trade name for this combination is Triumeq.

Triumeq is manufactured by ViiV Healthcare.

The generic name is Dolutegravir + Abacavir + Lamivudine.

The brand name is Triumeq.

It is manufactured in the UK and Europe by ViiV Healthcare, while licensed generic versions are manufactured in India by approved pharmaceutical companies for global supply.